Tolerability, pharmacokinetics and preliminary antitumor activity of intravenous UNBS 1450 in patients with advanced solid tumours or lymphoma.

Trial Profile

Tolerability, pharmacokinetics and preliminary antitumor activity of intravenous UNBS 1450 in patients with advanced solid tumours or lymphoma.

Recruiting
Phase of Trial: Phase I

Latest Information Update: 07 Jan 2009

At a glance

  • Drugs UNBS 1450 (Primary)
  • Indications Lymphoma; Solid tumours
  • Focus Adverse reactions; Biomarker; Pharmacokinetics
  • Sponsors Unibioscreen
  • Most Recent Events

    • 06 Mar 2008 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top